Patent AT-E401389-T1: [Translated] TRANSGENIC ANIMAL MODELS WITH ALTERED PHENOTYPE FOR ALZHEIMER'S DISEASE
A method of preparing a transgenic animal model with enhanced, accelerated pathology for Alzheimer's Disease (AD) and the transgenic animal made by the method is disclosed. The method includes producing an F1 generation by crossing a first and second transgenic parent each carrying a different expressible transgene for differing aspects of the same desired phenotype associated with AD pathology. The offspring of the F1 generation are then screened and those which carry a transgene from each parental transgenic animal resulting in an enhanced pathology for Alzheimer's Disease are selected. In a preferred embodiment the AD-associated pathology is for amyloid accumulation. In an embodiment a mutant presenilin transgene and a transgene for a mutant amyloid precursor protein are used. In a further embodiment the mutant presenilin transgene is the PS1 M146L mutation and the mutant amyloid precursor protein transgene is the Swedish mutation (APP695 isoform containing a K670N,M671L mutation (APP770 numbering)).
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[ "009:25" ] |
| contactPoint |
{ "fn": "NIH/NCBI Data Team", "@type": "vcard:Contact", "hasEmail": "mailto:info@ncbi.nlm.nih.gov" } |
| description | A method of preparing a transgenic animal model with enhanced, accelerated pathology for Alzheimer's Disease (AD) and the transgenic animal made by the method is disclosed. The method includes producing an F1 generation by crossing a first and second transgenic parent each carrying a different expressible transgene for differing aspects of the same desired phenotype associated with AD pathology. The offspring of the F1 generation are then screened and those which carry a transgene from each parental transgenic animal resulting in an enhanced pathology for Alzheimer's Disease are selected. In a preferred embodiment the AD-associated pathology is for amyloid accumulation. In an embodiment a mutant presenilin transgene and a transgene for a mutant amyloid precursor protein are used. In a further embodiment the mutant presenilin transgene is the PS1 M146L mutation and the mutant amyloid precursor protein transgene is the Swedish mutation (APP695 isoform containing a K670N,M671L mutation (APP770 numbering)). |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Official Data Source", "mediaType": "text/html", "description": "Access the complete Patent AT-E401389-T1: [Translated] TRANSGENIC ANIMAL MODELS WITH ALTERED PHENOTYPE FOR ALZHEIMER'S DISEASE on the official website.", "downloadURL": "https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401389-T1" } ] |
| identifier | https://healthdata.gov/api/views/cqvz-igb3 |
| issued | 2025-09-05 |
| keyword |
[ "chemistry", "innovation", "patent", "pubchem", "research" ] |
| landingPage | https://healthdata.gov/d/cqvz-igb3 |
| modified | 2025-09-06 |
| programCode |
[ "009:066" ] |
| publisher |
{ "name": "National Center for Biotechnology Information (NCBI)", "@type": "org:Organization" } |
| theme |
[ "NIH" ] |
| title | Patent AT-E401389-T1: [Translated] TRANSGENIC ANIMAL MODELS WITH ALTERED PHENOTYPE FOR ALZHEIMER'S DISEASE |
